Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 April 2013Website:
http://www.chimerix.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 30 min agoDividend
Analysts recommendations
Institutional Ownership
CMRX Latest News
DURHAM, N.C., July 05, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on July 1, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards to two new employees of non-statutory stock options to purchase up to a total of 120,000 shares of Chimerix's common stock. The Compensation Committee of Chimerix's Board of Directors approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing rule 5635(c)(4).
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.
Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3 K27M-mutated diffuse midline glioma. The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook.
Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expected $200 million in liquidity by the end of 2023.
Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andriole - President and CEO Josh Allen - Chief Technology Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Joel Beatty - Baird Ed White - H.C. Wainwright Soumit Troy - Jones Trading Joseph Thome - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2023 Earnings Conference Call.
Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for less than net cash on its balance sheet. An updated investment analysis on Chimerix, Inc. follows in the paragraphs below.
The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according to analysts at Baird. The firm initiated coverage of the North Carolina-based company with an Outperform rating and a $7 price target.
Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman - President and Chief Executive Officer Allen Melemed - Chief Medical Officer Mike Andriole - Chief Financial and Business Officer Josh Allen - Chief Technology Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Securities Ed White - H.C. Wainwright Troy Langford - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix First Quarter 2023 Earnings Conference Call.
What type of business is Chimerix?
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
What sector is Chimerix in?
Chimerix is in the Healthcare sector
What industry is Chimerix in?
Chimerix is in the Biotechnology industry
What country is Chimerix from?
Chimerix is headquartered in United States
When did Chimerix go public?
Chimerix initial public offering (IPO) was on 11 April 2013
What is Chimerix website?
https://www.chimerix.com
Is Chimerix in the S&P 500?
No, Chimerix is not included in the S&P 500 index
Is Chimerix in the NASDAQ 100?
No, Chimerix is not included in the NASDAQ 100 index
Is Chimerix in the Dow Jones?
No, Chimerix is not included in the Dow Jones index
When does Chimerix report earnings?
The next expected earnings date for Chimerix is 02 August 2024